A legion of prospective career-oriented reps stands at the gates, waiting to join the ranks of the pharmaceutical industry.
Lykos Therapeutics Reshuffles Board of Directors Following FDA Rejection of Midomafetamine Capsules
January 15th 2025During the transition period, Lykos will work with a number of shareholders to secure financing for an additional Phase III trial of midomafetamine capsules for post-traumatic stress disorder.